Variant report
Variant | esv2762279 |
---|---|
Chromosome Location | chr2:124827023-124840027 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs1213950 | chr2:124827023-124827024 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs189803465 | chr2:124827051-124827052 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs116654832 | chr2:124827094-124827095 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs564847124 | chr2:124827132-124827133 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs201268234 | chr2:124827137-124827138 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs11885688 | chr2:124827181-124827182 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
7 | rs114463462 | chr2:124827185-124827186 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs557212335 | chr2:124827195-124827196 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs529981563 | chr2:124827236-124827237 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs532148951 | chr2:124827267-124827268 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs2420439 | chr2:124827285-124827286 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
12 | rs115047334 | chr2:124827292-124827293 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs182795902 | chr2:124827345-124827346 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs144165383 | chr2:124827379-124827380 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs536431319 | chr2:124827380-124827381 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs569283512 | chr2:124827392-124827393 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs575096823 | chr2:124832830-124832831 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs180893155 | chr2:124832834-124832835 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs553128329 | chr2:124832842-124832843 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs112869072 | chr2:124832848-124832849 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs79047004 | chr2:124832873-124832874 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs567606903 | chr2:124832892-124832893 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs530759966 | chr2:124832895-124832896 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs544109437 | chr2:124832900-124832901 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs185150398 | chr2:124832904-124832905 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs529860947 | chr2:124832920-124832921 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs546666294 | chr2:124832953-124832954 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs566884836 | chr2:124832961-124832962 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs532525819 | chr2:124832972-124832973 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs552334621 | chr2:124832985-124832986 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs538177606 | chr2:124832997-124832998 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs534609953 | chr2:124833019-124833020 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs58790623 | chr2:124833022-124833023 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs548917107 | chr2:124833023-124833024 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs568644500 | chr2:124833079-124833080 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs371067319 | chr2:124833104-124833105 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs534425293 | chr2:124833176-124833177 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs561068678 | chr2:124833192-124833193 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs73954518 | chr2:124833231-124833232 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
40 | rs374473979 | chr2:124833252-124833253 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs145922855 | chr2:124833253-124833254 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs189416572 | chr2:124833276-124833277 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs544071999 | chr2:124833296-124833297 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs560876250 | chr2:124833304-124833305 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs574277409 | chr2:124833307-124833308 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs73954520 | chr2:124833321-124833322 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
47 | rs73954521 | chr2:124833338-124833339 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
48 | rs532452684 | chr2:124833356-124833357 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs181453667 | chr2:124833363-124833364 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs186421033 | chr2:124833377-124833378 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Breast cancer | 17603634 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ependymoma | 16718352 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Intellectual disability | 22102821 | CNVD |
Cancer | 20164919 | CNVD |
Autism | 22495311 | CNVD |
Autism | 18522746 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Seminomas | 18059402 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Myxofibrosarcoma | 16751306 | CNVD |
Breast cancer | 16272173 | CNVD |
Lung cancer | 18438408 | CNVD |
Mowat-Wilson syndrome | 21572526 | CNVD |
Disorders of sex development | 21048976 | CNVD |
epilepsy | 18472482 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Autism | 16446308 | CNVD |
Autism | 19401682 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Colorectal cancer | 16272173 | CNVD |
myoclonus epilepsy | 18472482 | CNVD |
Benign familial neonatal-infantile seizures | 18472482 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Mental retardation | 17621639 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Prostate cancer | 16573809 | CNVD |
Prostate cancer | 18632612 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Neurocytoma | 17123091 | CNVD |
Pancreatic ductal adenocarcinoma | 19077451 | CNVD |
Developmental delay | 21147756 | CNVD |
Bladder cancer | 21909424 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Breast cancer | 22522925 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:124826800-124827400 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
2 | chr2:124832800-124833400 | Enhancers | Fetal Adrenal Gland | Adrenal Gland |
3 | chr2:124834600-124835400 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
4 | chr2:124835400-124838800 | Weak transcription | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
5 | chr2:124836600-124839600 | Enhancers | Fetal Intestine Small | intestine |
6 | chr2:124836800-124837800 | Enhancers | Fetal Intestine Large | intestine |
7 | chr2:124837400-124838600 | Enhancers | Duodenum Mucosa | Duodenum |
8 | chr2:124837800-124839200 | Weak transcription | Fetal Intestine Large | intestine |
9 | chr2:124838000-124839400 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
10 | chr2:124838200-124839400 | Enhancers | Foreskin Keratinocyte Primary Cells skin03 | Skin |
11 | chr2:124838600-124839200 | Weak transcription | Duodenum Mucosa | Duodenum |
12 | chr2:124838800-124839200 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
13 | chr2:124838800-124839400 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
14 | chr2:124839000-124839400 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
15 | chr2:124839200-124839600 | Enhancers | Foreskin Keratinocyte Primary Cells skin02 | Skin |
16 | chr2:124839200-124839600 | Enhancers | Duodenum Mucosa | Duodenum |
17 | chr2:124839200-124839600 | Enhancers | Fetal Intestine Large | intestine |